Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Immune checkpoint inhibitors
14 evidence topics · 11 sources
Guideline recommendation on combination immunotherapy and patient selection
“Given the lack of a clear survival advantage in metastatic UM associated with nivolumab–ipilimumab versus pembrolizumab and the increased toxicity associated with the former, only selected patients fit enough for the combination and with predominant extrahepatic disease should be considered for the combination immunotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline summary of anti-PD-1 monotherapy outcomes in uveal melanoma
“Patients with metastatic UM have been excluded from most trials evaluating ICIs in cutaneous melanoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the safety profile of PD-1 inhibitors was better in UM compared with cutaneous melanoma, efficacy was comparatively disappointing, showing <5% ORR, median PFS of 3 months and 1-year OS ∼50%, likely due to low tumour mutational burden, poor antigen processing and presentation and the immune-suppressive tumour microenvironment in UM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline summary of phase 2 trials of nivolumab plus ipilimumab
“In two phase II studies in 52 and 33 patients, respectively, nivolumab–ipilimumab was associated with ORR of 11% and 18%, median PFS of 3 and 5.5 months and median OS of 12 and 19 months, respectively, after a median follow-up of ∼13 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Indirect comparison of tebentafusp, nivolumab plus ipilimumab, and pembrolizumab in first-line disease: guideline summary
“In the absence of randomised comparative studies, indirect comparisons of ICIs with tebentafusp in first-line metastatic UM have been conducted.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A propensity score analysis of two studies showed an OS benefit for tebentafusp versus nivolumab–ipilimumab (1-year OS rate of 73% versus 50%, respectively), independent of HLA status, and no significant difference in survival between pembrolizumab and nivolumab–ipilimumab (median OS and 1-year OS rate of 16.9 months and 60% versus 14.2 months and 52%, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Toxicity rates were higher with nivolumab–ipilimumab compared with pembrolizumab (23% versus 2%-5% treatment-related discontinuations and two versus no treatment-related deaths).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-line nivolumab plus ipilimumab: single-arm phase 2 trial of the Spanish Multidisciplinary Melanoma Group, 52 participants
“This was a single-arm, phase II trial led by the Spanish Multidisciplinary Melanoma Group (GEM) on nivo plus ipi for systemic treatment-naïve patients of age > 18 years, with histologically confirmed MUM, Eastern Cooperative Oncology Group-PS 0/1, and confirmed progressive metastatic disease (M1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nivo (1 mg/kg once every 3 weeks) and ipi (3 mg/kg once every 3 weeks) were administered during four inductions, followed by nivo (3 mg/kg once every 2 weeks) until progressive disease, toxicity, or withdrawal.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 52 patients with a median age of 59 years (range, 26-84 years) were enrolled.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end point was 12-month OS, which was 51.9% (95% CI, 38.3 to 65.5).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median OS and PFS were 12.7 months and 3.0 months, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Nivo plus ipi in the first-line setting for MUM showed a modest improvement in OS over historical benchmarks of chemotherapy, with a manageable toxicity profile.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Nivolumab plus ipilimumab: single-arm phase 2 trial of 35 participants
“This single-arm phase II study of nivolumab and ipilimumab in patients with metastatic uveal melanoma demonstrated an overall response rate (ORR) of 18%, a median progression-free survival of 5.5 months, and a median overall survival of 19.1 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-five patients were enrolled, and 33 patients were evaluable for efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 18%, including one confirmed complete response and five confirmed partial responses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For the 35 patients included in the study, the median OS was 19.1 months (95% CI, 9.6 months to NR), and the 1-year OS was 56% (95% CI, 38% to 71%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR in the 31 evaluable patients who were checkpoint naïve was 19%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nivolumab plus ipilimumab in practice: multicenter retrospective study of 89 participants
“We conducted a retrospective analysis of patients with metastatic UM (mUM) who received treatment with ipilimumab plus nivolumab across 14 academic medical centers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“89 eligible patients were identified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall response rate was 11.6%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS from treatment initiation was 15 months and median PFS was 2.7 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ipilimumab plus a PD-1 inhibitor at 16 German skin cancer centers: 64 participants
“The clinical data of 64 patients from 16 German skin cancer centers who met the inclusion criteria were investigated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The best overall response rate to combined checkpoint blockade was 15.6% with 3.1 and 12.5% complete and partial response, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median PFS was 3.0 months (95% CI 2.4–3.6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median OS was estimated to 16.1 months (95% CI 12.9–19.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
First-line pembrolizumab: prospective observational cohort of 17 participants
“In this prospective observational cohort single arm study, we investigated efficacy and safety of Pembrolizumab as first-line therapy for mUM.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Seventeen patients were enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two patients achieved partial response (11.7%), 6 a disease stabilization (35.3%), whereas 9 (53%) had a progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Toxicity was mild, without grade 3–4 side effects.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PD-1 or PD-L1 antibody monotherapy: multicenter retrospective series of 56 participants
“Safety and clinical efficacy outcomes including best overall response (BOR), progression-free survival (PFS), overall survival (OS) were determined retrospectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“we report clinical outcomes in a larger series of 56 patients treated at nine institutions with PD-1 (pembrolizumab or nivolumab) or PD-L1 (atezolizumab) antibodies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Objective tumor responses were observed in two patients for an overall response rate of 3.6% (95% CI 1.8-22.5%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median PFS was 2.6 months (95% CI 2.4-2.8 months) and the median OS was 7.6 months (95% CI 0.7-14.6 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PD-1 inhibitor monotherapy at 20 German skin cancer centres: 86 participants
“Patients with metastatic UM treated with either PD-1 inhibitor monotherapy or combined PD-1 inhibitor and ipilimumab (an anti-CTLA-4 monoclonal antibody) were included from 20 German skin cancer centres.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eighty-six patients were treated with PD-1 inhibitors only (n = 54 for pembrolizumab, n = 32 for nivolumab) with a centrally confirmed response rate of 4.7%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS was 14 months for pembrolizumab-treated and 10 months for nivolumab-treated patients (p = 0.765).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ipilimumab monotherapy: phase 2 DeCOG trial in pretreated and treatment-naïve participants
“We performed an open-label, multicenter, single-arm phase II clinical trial (DeCOG-trial) to further evaluate the efficacy and safety of 3mg/kg ipilimumab in treatment-naïve and pretreated patients with advanced UM seen in daily routine in interdisciplinary skin cancer units in Germany.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Forty five pretreated (85%) and eight treatment-naïve (15%) patients received at least one dose of ipilimumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS was 6.8 months (95% CI 3.7–8.1), median progression-free survival 2.8 months (95% CI 2.5–2.9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sixteen patients had stable disease (47%), none experienced partial or complete response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related AEs were observed in 35 patients (66%), including 19 grade 3–4 events (36%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ipilimumab monotherapy after prior treatment: expanded access program of 82 assessable participants
“Pre-treated patients with advanced uveal melanoma received ipilimumab 3 mg/kg through an expanded access programme, every 3 weeks for four doses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among 82 assessable patients, 4 (5%) had an immune-related objective response and 24 (29%) had immune-related stable disease lasting ≥3 months for an immune-related disease control rate of 34%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With a median follow-up of 5.6 months, median overall survival (OS) was 6.0 months and median progression-free survival (PFS) was 3.6 months.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Meta-analysis of response and survival by checkpoint inhibitor class
“Pooled ORR was 9.2% overall (95% CI 7.2-11.8) [4.1% for anti-CTLA4 (95% CI 2.1-7.7), 7.1% for anti-PD(L)1 (95% CI 4.5-10.9) and 13.5% for anti-CTLA4 plus anti-PD1 (95% CI 10.0-18.0)].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS was 11.5 months overall (95% CI 9.5-13.8) [8.0 months for anti-CTLA4 (95% CI 5.5-9.9), 11.7 months for anti-PD(L)1 (95% CI 9.0-14.0) and 16.0 months for ipilimumab plus anti-PD1 (95% CI 11.5-17.7) ( P < 0.001)].” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median PFS was 3.0 months overall (95% CI 2.9-3.1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote